



Certificate delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020

The project proposal 756828, BLOODART

IMPROVING BLOOD AND STEM CELL PROCESSING SYSTEM

Submitted under the Horizon 2020's **SME instrument phase 2** call **H2020-SMEInst-2016-2017** (**H2020-SMEINST-2-2016-2017**) of **13 October 2016** in the area of

Supporting innovative SMEs in the healthcare biotechnology sector

by

PROMEDART BIYOTEKNOLOJI VE OZEL SAGLIK HIZ. SAN. TIC. LTD STI

BAGLAR MAH. YALCIN KORES CAD. ERDINC BINALARI NO:22 A/3 BLOK K:1 34209 ISTANBUL Turkey

following evaluation by an international panel of independent experts

WAS SUCCESSFUL IN A HIGHLY COMPETITIVE EVALUATION PROCESS* AS A HIGH QUALITY PROJECT PROPOSAL

This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

Corina Cretu,

Commissioner for Regional Policy

Carlos Moedas,

Commissioner for Research, Science and Innovation

Cer?

Crete